Resumen: Incyte anuncia un dictamen favorable del CHMP sobre la crema Opzelura® (ruxolitinib) para tratar a los pacientes adultos con dermatitis atópica moderada
Friday, June 26, 2026 BiopharmaWatch Research 1 min read
Key Takeaway: Incyte has announced a favorable opinion from the Committee for Medicinal Products for Human Use (CHMP) regarding its cream Opzelura® (ruxolitinib). This treatment is aimed at adult patients suffering from moderate atopic dermatitis. The positive opinion may lead to expanded treatment options for this patient demographic.
Price reaction · baseline $113.75 (2026-06-26 close) · hit after-hours · clean, no other INCY news in the window
day 0 close
+0.8%
Market Sentiment Analysis
POSITIVE FACTORS
Incyte received a favorable opinion from the CHMP.
The cream Opzelura® (ruxolitinib) shows promise for treating moderate atopic dermatitis.
This decision could enhance treatment options for adult patients.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+44%
120-day peak, hindsight
Typical move
1.8%
average across 15 past catalysts
Lead asset
INCB013739
Phase 2 · Type 2 Diabetes
Full Press Release Details
MORGES, Suiza--(BUSINESS WIRE)--Incyte (Nasdaq: INCY) ha anunciado hoy que el Comité de Medicamentos de Uso Humano (Committee for Medicinal Products for Human Use, CHMP) de la Agencia Europea de Medicamentos (EMA) ha emitido un dictamen favorable en el que recomienda la autorización de la crema Opzelura®(ruxolitinib) para tratar la dermatitis atópica (DA) moderada en los pacientes adultos para quienes los corticosteroides tópicos (CT) y los inhibidores tópicos de la calcineurina (ITC) resultan insuficientes o inadecuados.
El comunicado en el idioma original es la versión oficial y autorizada del mismo. Esta traducción es solamente un medio de ayuda y deberá ser comparada con el texto en idioma original, que es la única versión del texto que tendrá validez legal.
Frequently Asked Questions
What is Opzelura® used for?
Opzelura® (ruxolitinib) is used to treat moderate atopic dermatitis in adults.
What did the CHMP decide about Opzelura®?
The CHMP issued a favorable opinion regarding the use of Opzelura® for treatment.
Who will benefit from Opzelura®?
Adult patients with moderate atopic dermatitis are the target beneficiaries.
What does a favorable CHMP opinion mean?
A favorable opinion from the CHMP can lead to expanded treatment options.